Home›Stock Screener›Novartis›Financial Statements

Novartis Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Novartis (NOVARTIND) reported revenue ₹354 Cr, net profit ₹95 Cr and EPS ₹37.74, with a net profit margin of 26.8% and ROE of 11.6%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review NOVARTIND earnings valuation to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 26.84% 2026 data
EBITDA Margin 26.55% 2026 data
Operating Margin 27.00% 2026 data
Return on Assets 9.71% 2026 data
Return on Equity 11.61% 2026 data

Balance Sheet Ratios

Current Ratio 48.00 2026 data
Equity Ratio 83.64% 2026 data
Asset Turnover 0.36 2026 data

NOVARTIND Revenue, Net Profit & EBITDA — Year-on-Year Growth

NOVARTIND YoY (March 2025 vs March 2026) — revenue -11.1%, net profit -5.9%, EBITDA -29.3%, expenses -1.9%. Explore NOVARTIND investment value to estimate fundamental worth using multiple valuation models.

Revenue Growth
-11.1%
Year-over-Year
Net Profit Growth
-5.9%
Year-over-Year
EBITDA Growth
-29.3%
Year-over-Year
Expense Growth
-1.9%
Year-over-Year
Assets Growth
+3.2%
Year-over-Year
Equity Growth
+4.2%
Year-over-Year
Operating Cash Flow Growth
-33.6%
Year-over-Year
Investing Cash Flow Growth
-109.1%
Year-over-Year
Financing Cash Flow Growth
+47.1%
Year-over-Year

NOVARTIND Income Statement — Revenue, EBITDA & Net Profit

Novartis revenue ₹354 Cr, EBITDA ₹94 Cr, net profit ₹95 Cr, EPS ₹37.74 (2026) — net profit margin 26.8%. For live price, earnings ratios and company overview, see Novartis stock price NSE.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 354 398 397 437 433 414 474 569 736 727 771 981
Expenses 260 265 270 314 373 355 426 478 570 631 656 877
EBITDA 94 133 127 123 60 60 48 91 166 96 115 104
Operating Profit Margin % 27.00% 26.00% 19.00% 17.00% 7.00% 7.00% 3.00% 3.00% -1.00% 4.00% 5.00% 0.00%
Depreciation 2 2 3 6 10 12 13 3 3 4 4 4
Interest 1 1 2 2 5 8 6 2 6 1 0 0
Profit Before Tax 130 130 123 115 -4 40 29 86 158 92 111 93
Tax 35 30 38 12 0 19 19 34 79 35 39 14
Net Profit 95 101 85 103 -4 21 10 52 78 57 73 79
Earnings Per Share (₹) 37.74 40.87 34.50 41.86 -1.51 8.46 4.08 20.97 28.43 19.10 62.04 24.75

NOVARTIND Balance Sheet — Assets, Liabilities & Shareholders' Equity

NOVARTIND total assets ₹978 Cr, total equity ₹818 Cr, total liabilities ₹ Cr (2026) — ROE 11.6%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 978 948 925 983 958 1,002 1,078 982 1,111 1,150 1,433 1,246
Current Assets 768 746 699 677 709 723 813 807 952 973 1,264 1,063
Fixed Assets 3 5 7 19 24 64 76 15 5 6 7 9
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 0
Investments 53 0 0 0 0 0 0 0 0 0 0 0
Other Assets 0 943 918 964 934 938 1,001 968 1,106 1,144 1,426 1,238
LIABILITIES
Total Liabilities
Current Liabilities 16 21 23 48 50 132 124 38 47 47 35 33
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 818 785 745 776 692 711 721 759 734 920 1,194 1,002
Share Capital 12 12 12 12 12 12 12 12 12 14 16 16
Reserves & Surplus 806 773 733 763 679 699 708 747 721 906 1,178 986

NOVARTIND Cash Flow Statement — Operating, Investing & Financing

Novartis operating cash flow ₹75 Cr, investing ₹-3 Cr, financing ₹-64 Cr, net cash flow ₹7 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 75 113 45 39 -69 -23 -194 161 -41 57 -60
Investing Activities -3 33 -153 87 95 56 274 69 424 -631 719
Financing Activities -64 -121 -31 -36 -37 -41 -30 -268 -332 -39 -38
Net Cash Flow 7 26 -139 90 -11 -9 50 -38 51 -613 622